Effect of salmeterol on patients' adherence to their prescribed refills for inhaled corticosteroids

Annals of Allergy, Asthma and Immunology

Volumn 84, Issue 3, 2000, Pages 324-328

  Kelloway, Judy S ^a,b   Wyatt, Richard ^c   DeMarco, Joanne ^d   Adlis, Susan ^e  

^a MedAdvisor Inc   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d HealthSystem Minnesota   (United States)

^e Institute for Research and Education   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; SALMETEROL;

ADOLESCENT; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CHILD; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL;

EID: 0034120775     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62781-0     Document Type: Article

References (42)

1. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma. Expert Panel Report II. Bethesda, Md; National Institutes of Health, National Heart, Lung, and Blood Institute; 1997. NIH publication 97-4051.
2. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219-224.
3. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of the addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153(5):1481-1488.
4. Weersink EJM, Douma RR, Postma DS, et al. Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma. Am J Respir Crit Care Med 1997;155:1231-1246.
5. Condemi JJ, Godstein S, Kalberg C, et al. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Ann Allergy Asthma Immunol 1999;82: 383-389.
6. Kemp JP, Cook DA, Incaudo GA, et al. Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. J Allergy Clin Immunol 1998;101(2Pt1):188-195.
7. Juniper EF, Johnston PR, Borkhoff CM, et al. Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol. Am J Respir Crit Care Med 1995;151(1):66-70.
8. Wenzel SE, Lumry W, Manning M, et al. Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma. Ann Allergy Asthma Immunol 1998;80(6):463-470.
9. Haynes RB. Introduction. In: Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore: Johns Hopkins University Press, 1979:1-7.
10. Legorreta AP, Christian-Herman J, O'Connor R, et al. Compliance with national asthma management guidelines and specialty care: a health maintenance organization experience. Arch Intern Med 1998;158(5):457-464.
11. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997;102(2A):43-49.
12. Sclar DA. Improving medical compliance: a review of selected issues. Clin Ther 1991;13(4):436-440.
13. Taytard A. Assessing compliance in asthma patients. Conference report: Assessing and ensuring drug compliance in chronic respiratory diseases. Eur Respir J 1992;5:125-126.
14. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997; 50:105-116.
15. Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J 1995;130: 572-579.
16. Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med 1984; 100:258-268.
17. O'Brien MK, Petrie K, Raeburn J. Adherence to medication regimens: updating a complex medical issue. Med Care 1992;49(4):435-454.
18. Cochrane GM. Therapeutic compliance in asthma; its magnitude and implications. Conference report: assessing and ensuring drug compliance in chronic respiratory diseases. Eur Respir J 1992;5:122-124.
19. Cramer JA. In: Cramer JA, Spilker B, eds. Patient compliance in medical practice and clinical trials. 1991;3-17:37-56.
20. van Ganse E, Hubloue I, Vincken W, et al. Actual use of inhaled corticosteroids and risk of hospitalisation: a case-control study. Eur J Clin Pharmacol 1997;51(6):449-454.
21. Cochrane GM. Compliance and outcomes in patients with asthma. Drugs 1996;52(Suppl 6):12-19.
22. Apter AJ, Reisine ST, Affleck G, et al. Adherence with twice-daily dosing of inhaled corticosteroids. Am J Respir Crit Care Med 1998;157(6 Pt 1): 1810-1817.
23. Bosley CM, Parry DT, Cochrane GM. Patient compliance with inhaled medication: does combining beta-agonists with corticosteroids improve compliance? [see comments]. Eur Respir J 1994;7:504-509.
24. Dolce JJ, Crisp C, Manzella B, et al. Medication adherence patterns in chronic obstructive pulmonary disease. Chest 1991;99(4):837-841.
25. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patient's compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994;154:1349-1352.
26. Kehoe WA, Katz RC. Health behaviors and pharmacotherapy. Ann Pharmacother 1998;32:1076-1086.
27. Rand CS, Wise RA, Nides M, et al. Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis 1992; 146:1559-1564.
28. Creer TL, Levstek D. Medication compliance and asthma: overlooking the trees because of the forest. J Asthma 1996;33(4):203-211.
29. Podell RN, Gary LR. Compliance: a problem in medical management. Am Fam Physician 1976;13:74-80.
30. Woller W, Kruse J, Winter P, et al. Cortisone image and emotional support by key figures in patients with bronchial asthma. Psychother Psychosom 1993;59(3-4):190-196.
31. van der Palen J, Klein JJ, Rovers MM. Compliance with inhaled medication and self-treatment guidelines following a self-management programme in adult asthmatics. Eur Respir J 1997; 10(3):652-657.
32. Tettersell MJ. Asthma patients' knowledge in relation to compliance with drug therapy. J Adv Nurs 1993;18:103-113.
33. Chetta A, Foresi A, Del Donno M, et al. Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest 1997;111: 852-857.
34. Jeffery PK, Godfrey RW, Adelroth E, et al. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. Am Rev Respir Dis 1992;145: 890-899.
35. Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994;331: 700-705.
36. Selroos O, Pietnalho A, Lofross A-B, Riska H. Effect of early vs. late intervention with inhaled corticosteroids in asthma. Chest 1995;108:1228-1234.
37. vanEssen-Zandvliet EF, Hughes MD, Waalkens HJ, et al. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am Rev Respir Dis 1992;146:546-554.
38. Position statement: Safety and appropriate use of salmeterol in the treatment of asthma. American Academy of Allergy, Asthma, and Immunology Committee on Drugs. J Allergy Clin Immunol 1996;98(3):475-480.
39. Brogden RN, Faulds D. Salmeterol xinofoate: a review of its pharmacologic properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991;42(5):895-912.
40. Lemanske RF, Allen DB. Choosing a long-term controlled medication in childhood asthma: the proverbial two-edged sword [Letter]. Am J Respir Crit Care Med 1997;156:685-687.
41. Bone RC. A word of caution regarding a new long-acting bronchodilator [Letter]. JAMA 1994;271(18):1447-1448.
42. Horn CR. The assessment of therapeutic compliance by asthma patients. Conference report: assessing and ensuring drug compliance in chronic respiratory diseases. Eur Respir J 1992;5:126-127.